FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:482-492 January 29, 2004 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective by Snyder, P. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Hypogonadism is a clinical condition in which low levels of serum testosterone are found in association with specific signs and symptoms, including diminished libido and sense of vitality, erectile dysfunction, reduced muscle mass and bone density, depression, and anemia (Table 1). When hypogonadism occurs in an older man, the condition is often called andropause, or androgen deficiency of the aging male.

View this table: [in this window] [in a new window]   Table 1. Hypogonadism.

 
Hypogonadism affects an estimated 2 million to 4 million men in the United States; its prevalence increases with age (Figure 1). ^1,2 However, it has been estimated that only 5 percent of affected men currently . . . [Full Text of this Article]

Forms of Testosterone Available for Administration

Risks of Testosterone-Replacement Therapy

Testosterone Supplementation and Cardiovascular Risk

Coronary Artery Disease

Lipid Profiles

Polycythemia

Testosterone-Replacement Therapy and the Prostate

Benign Prostatic Hyperplasia

Prostate Cancer

PSA

Other Potential Adverse Effects

Hepatic Effects

Sleep Apnea

Miscellaneous Effects of Testosterone

Monitoring during Therapy

Source Information

From the Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School — both in Boston.

Address reprint requests to Dr. Morgentaler at 1 Brookline Pl., Suite 624, Brookline, MA 02445, or at amorgent@caregroup.harvard.edu.

Related Letters:

Risks of Testosterone Replacement
Shames D. A., Schaeffer E. M., Walsh P. C., Redmond G., Harris R. M., Morgentaler A., Rhoden E. L.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2004-2006, May 6, 2004. Correspondence

This article has been cited by other articles:

• Laghi, F., Adiguzel, N., Tobin, M. J. (2009). Endocrinological derangements in COPD. Eur Respir J 34: 975-996 [Abstract] [Full Text]  
• Ribeiro, R. S., Abucham, J. (2009). Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur J Endocrinol 161: 163-169 [Abstract] [Full Text]  
• Theodoraki, A., Bouloux, P.-M. (2009). Testosterone therapy in men. Menopause Int 15: 87-92 [Abstract] [Full Text]  
• Vainionpaa, K. J. (2009). Finnish Commercial Web-Based Information on Male Menopause and Male Hormone Therapy. Current Sociology 57: 291-307 [Abstract]  
• Carrero, J. J., Qureshi, A. R., Parini, P., Arver, S., Lindholm, B., Barany, P., Heimburger, O., Stenvinkel, P. (2009). Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients. J. Am. Soc. Nephrol. 20: 613-620 [Abstract] [Full Text]  
• Vajda, E. G., Lopez, F. J., Rix, P., Hill, R., Chen, Y., Lee, K.-J., O'Brien, Z., Chang, W. Y., Meglasson, M. D., Lee, Y.-H. (2009). Pharmacokinetics and Pharmacodynamics of LGD-3303 [9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an Orally Available Nonsteroidal-Selective Androgen Receptor Modulator. J. Pharmacol. Exp. Ther. 328: 663-670 [Abstract] [Full Text]  
• Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., Morley, J. E., Schulman, C., Thompson, I. M., Weidner, W., Wu, F. C. W. (2009). Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. J Androl 30: 1-9 [Full Text]  
• Barry, P. J., Waterhouse, D. F., Reilly, C. M., McKenna, T. J., McKone, E. F., Gallagher, C. G. (2008). Androgens, Exercise Capacity, and Muscle Function in Cystic Fibrosis. Chest 134: 1258-1264 [Abstract] [Full Text]  
• Wang, C, Nieschlag, E, Swerdloff, R, Behre, H M, Hellstrom, W J, Gooren, L J, Kaufman, J M, Legros, J-J, Lunenfeld, B, Morales, A, Morley, J E, Schulman, C, Thompson, I M, Weidner, W, Wu, F C W (2008). Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159: 507-514 [Full Text]  
• Rice, D., Brannigan, R. E., Campbell, R. K., Fine, S., Jack, L. Jr, Nelson, J. B., Regan-Klich, J. (2008). Men's Health, Low Testosterone, and Diabetes: Individualized Treatment and a Multidisciplinary Approach. The Diabetes Educator 34: 97S-112S [Abstract] [Full Text]  
• Farrell, J. B., Deshmukh, A., Baghaie, A. A. (2008). Low Testosterone and the Association With Type 2 Diabetes. The Diabetes Educator 34: 799-806 [Abstract] [Full Text]  
• Loves, S., Ruinemans-Koerts, J., de Boer, H. (2008). Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 158: 741-747 [Abstract] [Full Text]  
• Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., Jerums, G. (2008). Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes. J. Clin. Endocrinol. Metab. 93: 1834-1840 [Abstract] [Full Text]  
• Wald, M., Miner, M., Seftel, A. D. (2008). State of the Art Reviews: Male Menopause: Fact or Fiction?. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2: 132-141 [Abstract]  
• Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., van der Schouw, Y. T. (2008). Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men: A Randomized Controlled Trial. JAMA 299: 39-52 [Abstract] [Full Text]  
• McVary, K. T. (2007). Erectile Dysfunction. NEJM 357: 2472-2481 [Full Text]  
• Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., Day, N. (2007). Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694-2701 [Abstract] [Full Text]  
• Yeap, B. B, Almeida, O. P, Hyde, Z., Norman, P. E, Chubb, S A P., Jamrozik, K., Flicker, L. (2007). In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol 156: 585-594 [Abstract] [Full Text]  
• Deschepper, C. F., Llamas, B. (2007). Hypertensive Cardiac Remodeling in Males and Females: From the Bench to the Bedside. Hypertension 49: 401-407 [Full Text]  
• Morgentaler, A. (2007). Guideline for Male Testosterone Therapy: A Clinician's Perspective. J. Clin. Endocrinol. Metab. 92: 416-417 [Full Text]  
• Ostrowski, J., Kuhns, J. E., Lupisella, J. A., Manfredi, M. C., Beehler, B. C., Krystek, S. R. Jr., Bi, Y., Sun, C., Seethala, R., Golla, R., Sleph, P. G., Fura, A., An, Y., Kish, K. F., Sack, J. S., Mookhtiar, K. A., Grover, G. J., Hamann, L. G. (2007). Pharmacological and X-Ray Structural Characterization of a Novel Selective Androgen Receptor Modulator: Potent Hyperanabolic Stimulation of Skeletal Muscle with Hypostimulation of Prostate in Rats. Endocrinology 148: 4-12 [Abstract] [Full Text]  
• Manassero, F., Erba, P., Mariani, G., Mogorovich, A., Giannarini, G., Selli, C. (2007). Metastatic Prostate Cancer After Orchiectomy, Radiotherapy, and Testosterone Replacement in a Patient With Bilateral Seminoma. J Androl 28: 10-12 [Full Text]  
• Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., Macairan, M. L., Nelson, P. S. (2006). Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial.. JAMA 296: 2351-2361 [Abstract] [Full Text]  
• Lewis, B. H., Legato, M., Fisch, H. (2006). Medical Implications of the Male Biological Clock.. JAMA 296: 2369-2371 [Full Text]  
• Spivak, J. L. (2006). Erythropoietin Resistance During Androgen Deficiency--Reply. Arch Intern Med 166: 1923-1924 [Full Text]  
• Estrada, M., Varshney, A., Ehrlich, B. E. (2006). Elevated Testosterone Induces Apoptosis in Neuronal Cells. J. Biol. Chem. 281: 25492-25501 [Abstract] [Full Text]  
• Shores, M. M., Matsumoto, A. M., Sloan, K. L., Kivlahan, D. R. (2006). Low Serum Testosterone and Mortality in Male Veterans.. Arch Intern Med 166: 1660-1665 [Abstract] [Full Text]  
• Ferrucci, L., Maggio, M., Bandinelli, S., Basaria, S., Lauretani, F., Ble, A., Valenti, G., Ershler, W. B., Guralnik, J. M., Longo, D. L. (2006). Low testosterone levels and the risk of anemia in older men and women.. Arch Intern Med 166: 1380-1388 [Abstract] [Full Text]  
• Shimon, I., Lubina, A., Gorfine, M., Ilany, J. (2006). Feedback Inhibition of Gonadotropins by Testosterone in Men With Hypogonadotropic Hypogonadism: Comparison to the Intact Pituitary-Testicular Axis in Primary Hypogonadism. J Androl 27: 358-364 [Abstract] [Full Text]  
• Wald, M., Meacham, R. B., Ross, L. S., Niederberger, C. S. (2006). Testosterone Replacement Therapy for Older Men. J Androl 27: 126-132 [Full Text]  
• (2006). Testosterone Replacement Therapy for Male Aging: ASA Position Statement. J Androl 27: 133-134 [Full Text]  
• Laghi, F. (2005). Low Testosterone in Chronic Obstructive Pulmonary Disease: Does It Really Matter?. Am. J. Respir. Crit. Care Med. 172: 1069-1070 [Full Text]  
• Razmara, A., Krause, D. N., Duckles, S. P. (2005). Testosterone augments endotoxin-mediated cerebrovascular inflammation in male rats. Am. J. Physiol. Heart Circ. Physiol. 289: H1843-H1850 [Abstract] [Full Text]  
• Kaufman, J. M., Vermeulen, A. (2005). The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications. Endocr. Rev. 26: 833-876 [Abstract] [Full Text]  
• Parsons, J. K., Carter, H. B., Platz, E. A., Wright, E. J., Landis, P., Metter, E. J. (2005). Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy. Cancer Epidemiol. Biomarkers Prev. 14: 2257-2260 [Abstract] [Full Text]  
• Gonzales, R. J., Ghaffari, A. A., Duckles, S. P., Krause, D. N. (2005). Testosterone treatment increases thromboxane function in rat cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 289: H578-H585 [Abstract] [Full Text]  
• Thethi, T. K., Asafu-Adjaye, N. O., Fonseca, V. A. (2005). Erectile Dysfunction. Clin. Diabetes 23: 105-113 [Abstract] [Full Text]  
• Galobardes, B., Smith, G. D., Jeffreys, M., Kinra, S., McCarron, P. (2005). Acne in Adolescence and Cause-specific Mortality: Lower Coronary Heart Disease but Higher Prostate Cancer Mortality: The Glasgow Alumni Cohort Study. Am J Epidemiol 161: 1094-1101 [Abstract] [Full Text]  
• Mendelsohn, M. E., Karas, R. H. (2005). Molecular and Cellular Basis of Cardiovascular Gender Differences. Science 308: 1583-1587 [Abstract] [Full Text]  
• Nuver, J., Smit, A. J., Wolffenbuttel, B. H.R., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., Gietema, J. A. (2005). The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer. JCO 23: 3718-3725 [Abstract] [Full Text]  
• Maalouf, N. M., Shane, E. (2005). Osteoporosis after Solid Organ Transplantation. J. Clin. Endocrinol. Metab. 90: 2456-2465 [Abstract] [Full Text]  
• Laghi, F., Antonescu-Turcu, A., Collins, E., Segal, J., Tobin, D. E., Jubran, A., Tobin, M. J. (2005). Hypogonadism in Men with Chronic Obstructive Pulmonary Disease: Prevalence and Quality of Life. Am. J. Respir. Crit. Care Med. 171: 728-733 [Abstract] [Full Text]  
• Laghi, F., Langbein, W. E., Antonescu-Turcu, A., Jubran, A., Bammert, C., Tobin, M. J. (2005). Respiratory and Skeletal Muscles in Hypogonadal Men with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 171: 598-605 [Abstract] [Full Text]  
• Dunn, B. K., Wickerham, D. L., Ford, L. G. (2005). Prevention of Hormone-Related Cancers: Breast Cancer. JCO 23: 357-367 [Abstract] [Full Text]  
• Er, F., Michels, G., Gassanov, N., Rivero, F., Hoppe, U. C. (2004). Testosterone Induces Cytoprotection by Activating ATP-Sensitive K+ Channels in the Cardiac Mitochondrial Inner Membrane. Circulation 110: 3100-3107 [Abstract] [Full Text]  
• MacLusky, N. J., Hajszan, T., Leranth, C. (2004). Effects of Dehydroepiandrosterone and Flutamide on Hippocampal CA1 Spine Synapse Density in Male and Female Rats: Implications for the Role of Androgens in Maintenance of Hippocampal Structure. Endocrinology 145: 4154-4161 [Abstract] [Full Text]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]  
• Shames, D. A., Schaeffer, E. M., Walsh, P. C., Redmond, G., Harris, R. M., Morgentaler, A., Rhoden, E. L. (2004). Risks of Testosterone Replacement. NEJM 350: 2004-2006 [Full Text]  
• (2004). Testosterone in Older Men: Replay of the Estrogen Story?. JWatch Gastroenterology 2004: 6-6 [Full Text]  
• (2004). Testosterone in Older Men: Replay of the Estrogen Story?. JWatch Psychiatry 2004: 8-8 [Full Text]  
• (2004). Testosterone in Older Men: Replay of the Estrogen Story?. JWatch General 2004: 2-2 [Full Text]